Background {#Sec1}
==========

Malaria remains a major global health problem. Despite malaria control achievements over the last 20 years \[[@CR1]\], recent data suggest that the global response and successful control of malaria may have plateaued, particularly in Africa \[[@CR2]\]. According to the World Health Organization (WHO), the number of malaria cases reported from the ten highest burden African countries, including Uganda, increased by 3.5 million in 2017 \[[@CR2]\]. In Uganda, efforts to scale-up coverage of malaria control interventions, through mass distribution of long-lasting insecticidal nets (LLINs), indoor residual spraying of insecticides (IRS), and effective case management with artemisinin-based combination therapy (ACT), have yielded positive results \[[@CR3], [@CR4]\]. However, malaria control gains have been difficult to sustain \[[@CR5], [@CR6]\] and the burden of malaria remains high \[[@CR2], [@CR7]\]. Innovative measures have been called for to achieve sustainable malaria control in Uganda and elsewhere in Africa \[[@CR8], [@CR9]\].

Children under five are at high risk of malaria in endemic areas and have typically been targeted for malaria control interventions, along with pregnant women. However, this approach overlooks school-aged children whose burden of disease is also important \[[@CR10]\]; they are at risk for asymptomatic malaria infections \[[@CR11]\], often have the highest parasite prevalence within populations \[[@CR12], [@CR13]\], and are important contributors to the infectious reservoir for onward transmission of malaria \[[@CR14], [@CR15]\]. Moreover, as malaria control interventions are scaled-up, and transmission intensity and consequently the level of acquired immunity in the population fall, the peak age of clinical malaria may shift from the very young, to include older school-aged children \[[@CR16]\]. Thus, malaria morbidity and mortality may paradoxically rise in school-aged children as malaria is controlled, highlighting the need to focus on this age group as malaria control intensifies \[[@CR17]\].

Intermittent preventive treatment (IPT) is a well-established malaria control intervention, which is recommended for pregnant women and infants. IPT of malaria in children under-five has also been operationalized as seasonal malaria chemoprevention (SMC) in West Africa. Chemoprevention is not currently policy for school-aged children, but extending SMC programmes to include older children has been investigated within the Sahel region of Africa \[[@CR18], [@CR19]\]. Evidence from Uganda and elsewhere suggests that IPT of malaria in schoolchildren provides significant health benefits and may improve cognitive function \[[@CR20]--[@CR23]\]. IPT of school-aged children also has the potential to reduce the infectious reservoir \[[@CR22], [@CR24]\]. Although momentum for chemoprevention of school-aged children is growing, more evidence is needed to help guide policy-makers.

To further evaluate IPT of malaria in schoolchildren, a cluster randomized trial was conducted in Jinja, Uganda in 2014--2015. Children enrolled from intervention schools received monthly IPT with dihydroartemisinin-piperaquine (DP) for up to 6 rounds of treatment. The primary objective of the trial was to evaluate the impact of IPT of schoolchildren on community-level indicators of malaria transmission, as measured in a post-intervention cross-sectional community survey and continuous entomological surveillance; these results have been reported previously \[[@CR24]\]. Here, the secondary outcomes from school-based surveys are presented, adding to the evidence base for chemoprevention in older, school-aged children.

Methods {#Sec2}
=======

Study site {#Sec3}
----------

The study was carried out in Jinja district in eastern Uganda, where malaria transmission is perennial (Fig. [1](#Fig1){ref-type="fig"}). At baseline, the annual entomologic inoculation rate (assessed from January to April 2014) was 58.9 infective bites per person per year \[[@CR24]\], and parasite prevalence in children enrolled in intervention schools (assessed from April to June 2014) was 43.2% (95% confidence interval \[CI\] 36.9--49.7%) with substantial heterogeneity between schools (ranging from 0 to 75%).Fig. 1Map of the study area

Clusters and randomization {#Sec4}
--------------------------

Digitally enumerated maps were used to define clusters, including one primary school plus the 100 closest households surrounding the school \[[@CR24]\]. One school was included per cluster and a buffer zone of 500 m was implemented between clusters. Public schools were prioritized. In total, 84 schools were included (72 public and 12 private schools). Clusters were assigned randomly in a 1:1 allocation ratio to intervention or control in a parallel design by the trial statistician based in London. Restricted randomization was applied using Stata/SEv12 software aiming to balance assignment of trial arms between sub-counties, and school type (public or private). Allocation of primary schools to the two study arms was not masked.

IPT intervention {#Sec5}
----------------

Prior to the study, team members met with key stakeholders in health and education at the national and district levels to sensitize them to the trial using an information sheet. Verbal consent to participate was obtained from headteachers of all schools, and copies of the school registers were obtained from intervention schools. Recruitment for the IPT intervention was carried out continuously from March to December 2014.

Study personnel met with parents/guardians to review initial eligibility criteria, including: (1) able to locate parent/guardian, (2) enrolled in intervention school, (3) age ≥ 5 years (4) no known allergy to DP, (5) no menarche (female students), (6) no history of cardiac problems or fainting, (7) no family history of long QT syndrome, (8) not currently using medications known to prolong the QT interval, and (9) willingness of parent/guardian to provide written informed consent. If these criteria were met, children were reviewed individually at school by study personnel for the final criteria, including: (1) able to locate student, (2) no menarche (female students), (3) weight ≥ 11 kg, and (4) provision of written assent by student (aged 8 years or above). Children who passed screening underwent a brief physical examination, including measurement of weight and were fingerprinted to facilitate identification for future IPT treatment.

Participants in the IPT intervention received DP (Duo-Cotexcin, Holley Cotec Pharmaceuticals) monthly for up to 6 rounds of treatment (June to December 2014). DP was administered by study personnel orally once daily for 3 days, using full-strength DP tablets (40/320 mg), according to weight-based guidelines (11--20 kg: 40 mg/320 mg daily; 21--30 kg: 60 mg/540 mg daily; 31--40 kg: 80 mg/640 mg daily; ≥ 41 kg: 120 mg/960 mg daily). All treatments were directly observed. The trial was open-label, and no placebo treatment was provided in the control schools.

School survey {#Sec6}
-------------

A cross-sectional survey of children from each participating school was conducted toward the end of the intervention (November--December 2014). A random sample of children was selected from each school register. Recruitment and screening were stratified by class, to ensure equitable distribution of participants from all classes (P1--P7), until the target sample size of children per cluster was reached. A similar survey was conducted at baseline prior to the intervention delivery and was used to inform sample size calculations.

Study personnel invited parents/guardians of selected children for a meeting at the school to screen for eligibility criteria, including: (1) enrolled in a participating primary school, and (2) agreement of parents/guardians to provide informed consent. If these criteria were met, study personnel interviewed each child individually at school for the final criteria, including: (1) able to locate student and (2) provision of written assent by student (aged 8 years or above). Children were excluded if they could not be located on more than 3 occasions.

If selection criteria were met, a brief questionnaire was administered to collect information on age, gender, bed net use, location of residence, and a brief food history. Participants had their temperature measured, and a finger-prick blood sample was obtained for a thick blood smear and haemoglobin measurement (in every fifth participant) using a portable spectrophotometer (HemoCue, Anglom, Sweden). RDTs were performed on participants with fever (tympanic membrane temperature of ≥ 38.0 °C) or history of fever in the past 48 h (*CareStart*™ Malaria HRP-2 *P. falciparum*; ACCESSBIO). Children with a positive RDT were treated with artemether--lumefantrine unless they exhibited signs of severe malaria, in which case they were referred to appropriate health facilities. Detailed records of school attendance were collected from both intervention and control schools.

Laboratory procedures {#Sec7}
---------------------

Thick blood smears were stained with 2% Giemsa for 30 min and read by experienced laboratory technologists, who were not aware of study arm assignments. Parasite and gametocyte densities were calculated from thick blood smears by counting the number of asexual parasites and gametocytes, respectively, per 200 leukocytes (or per 500, if the count was less than 10 parasites or gametocytes per 200 leukocytes), assuming a leukocyte count of 8000/μl. A thick blood smear was considered negative when the examination of 100 high power fields did not reveal asexual parasites or gametocytes. For quality control, all slides were read by a second microscopist and a third reviewer settled discrepant readings.

Outcome measures {#Sec8}
----------------

The primary outcome among school children (a key secondary outcome of the trial) was prevalence of asexual parasitaemia, as measured by microscopy of individual blood smears. Secondary outcomes were prevalence of gametocytaemia, prevalence of anaemia \[[@CR25]\], mean haemoglobin, and school attendance.

Sample size estimates {#Sec9}
---------------------

Sample size was determined for the trial's secondary outcome, smear positive microscopy among school children, and was refined in October 2014 after results from the baseline survey were available. Thirteen randomly selected children in each of the 84 clusters (1092 total), had over 80% power at significance level 5% to detect a relative reduction in parasite prevalence of 35%, corresponding to an absolute difference in parasite prevalence of 11.5% (33% vs 21.5%), assuming a coefficient of variation between clusters of 0.50.

Statistical analysis {#Sec10}
--------------------

A secondary objective of the trial was to evaluate the impact of IPT for malaria in schoolchildren on clinical malaria indicators, aiming to test the hypothesis that the prevalence of asexual parasitaemia would be lower in the children enrolled in intervention schools than in those enrolled in control schools. The plans for the analysis presented here were outlined a priori in the statistical analysis plan for the trial. Data were analysed at the individual-level due to the large number of clusters per trial arm \[[@CR26]\] and statistical methods which accounted for within-cluster correlation were used in all analyses. Prevalence outcomes were analysed using generalized linear Poisson models with log link function \[[@CR27]\], incorporating a cluster-level random intercept and quantified using prevalence risk ratios. For other secondary quantitative outcomes, linear regression models were used. The effect of the intervention was quantified by calculation of difference in mean outcome. Rate ratios were used to describe the effect of the intervention on rates. Secondary analyses were conducted post hoc to assess whether the effect of the intervention differed by age group, geographical locality, or timing since last dose of DP. Tests for interaction were conducted, as was a per protocol analysis.

Ethical approval {#Sec11}
----------------

The trial was approved by the Ugandan National Council for Science and Technology (UNCST Ref HS 1530), Makerere University School of Biomedical Sciences Research & Ethics Committee (SBS REC 145), London School of Hygiene and Tropical Medicine Ethics Committee (LSHTM Ref 6509), School of Biological and Biomedical Sciences Ethics Committee, Durham University (DU SBBS/EC/STARTv5.0/June15) and University of California, San Francisco Committee on Human Research (UCSF CHR Ref 074826). Sponsorship and insurance were provided by the LSHTM's Clinical Trials Sub-Committee (Ref QA380). The trial was overseen by an independent Data and Safety Monitoring Board and a Trial Steering Committee.

Role of the funding source {#Sec12}
--------------------------

The funders played no role in the design of the study; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Results {#Sec13}
=======

IPT intervention recruitment and delivery {#Sec14}
-----------------------------------------

Of the 84 primary schools participating in the trial, most were public (85.7%). There were 23,280 children listed on the registers for the 42 intervention schools (mean 554, range 131--1521) vs 21,299 listed for the control schools (mean 507, range 113--1251). As previously reported \[[@CR24]\], a total of 89,823 single doses of DP were administered to 10,079 (43.3%) children from 30 June to 12 December 2014; of these, 9286 (92.1%) received at least one full 3-day course of DP. The trial was completed as planned.

School survey recruitment {#Sec15}
-------------------------

The final school survey was conducted from 13 November to 5 December 2014 (Fig. [2](#Fig2){ref-type="fig"}). Characteristics of participants (n = 1092, 13 per cluster) were similar across both study arms (Table [1](#Tab1){ref-type="table"}). A majority of children in both arms resided in rural areas within Jinja district. Most (80%) children enrolled from the intervention arm reported that they were enrolled in the IPT intervention. However, only 378 (69.2%) received any DP, and 356 (65.2%) received at least one full 3-day course of DP, while only 15 (2.8%) received the maximum number of doses in all 6 rounds, before the school survey. Of those who received any DP, there was wide variation in the timing of the last dose of DP before enrollment into the school survey (ranging from 1 to 113 days, with a mean of 15.3 \[SD 16\] days). Overall, 155 (28.4%) children received DP within 14 days of the survey. Only 38.4% of children reported that they had slept under a bed net the previous night.Fig. 2Trial profile Table 1Characteristics of participants surveyed in the final school surveyCharacteristicControl (n = 546)Intervention (n = 546)Age, years (mean, SE)10.5 (0.08)10.4 (0.08) 5--10 years276 (50.5%)290 (53.1%) 11--18 years270 (49.5%)256 (46.9%)Female285 (52.2%)260 (47.6%)Region^a^ Urban area  Jinja town91 (16.7%)143 (26.2%) Rural areas  Buwenge169 (31.0%)130 (23.8%)  Kakira/Busedde117 (21.4%)130 (23.8%)  Nile River169 (31.0%)143 (26.2%)Enrolled in the intervention^b^0 (0%)437 (80.0%)Slept under a bednet the previous night^b^194 (35.5%)225 (41.2%)Temperature (°C), mean (SE)37.1 (0.04)37.1 (0.04)^a^Comparing urban vs rural areas, adjusting for clustering, *p* value = 0.29^b^Missing for one child in the intervention arm

Impact on parasite prevalence {#Sec16}
-----------------------------

The prevalence of parasitaemia by microscopy was lower in the intervention than the control arm (intention-to-treat \[ITT\]: 9.2% vs 44.1%, adjusted risk ratio \[aRR\] 0.22 \[95% CI 0.16‒0.30\], p \< 0.001) (Table [2](#Tab2){ref-type="table"}). Similar results were observed when the data were stratified by age, however, differences were noted when stratified by area (Table [2](#Tab2){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). In the rural areas, children in the intervention arm were much less likely to be parasitaemic than those in the control arm (ITT: 10.4% vs 51.2%; aRR 0.20 \[95% CI 0.14‒0.29, p \< 0.001), while in the urban area of Jinja town, the difference between the two study arms was less marked (ITT: 5.6% vs 8.8%; aRR 0.65 \[95% CI 0.28‒1.54\], p = 0.33). Parasite prevalence varied widely by school (0% to 92%) and the coefficient of variation of parasite prevalence between the control clusters, k, was estimated to be 0.077. In the per-protocol analysis (Table [2](#Tab2){ref-type="table"}), which only included children in the intervention arm if they reported that they had been enrolled in the intervention, similar results were seen, but the difference in parasite prevalence between the intervention and control arms was even more pronounced, with the exception of the results for the urban area.Table 2Effect of the IPT intervention on parasite prevalence in the final school surveyn+/NPrevalence (%)Unadjusted risk ratio (95% CI)pAdjusted risk ratio (95% CI)^a^pIntention to treat analysis All ages  Control241/54644.111  Intervention50/5469.20.21 (0.14--0.30)\< 0.0010.22 (0.16--0.30)\< 0.001 5--10 years^b^  Control122/27644.211  Intervention23/2907.90.18 (0.12--0.28)\< 0.0010.19 (0.13--0.29)\< 0.001 11--18 years^b^  Control119/27044.111  Intervention27/25610.60.24 (0.16--0.36)\< 0.0010.25 (0.17--0.37)\< 0.001 Urban area^c^  Control8/918.811  Intervention8/1435.60.64 (0.26--1.58)0.330.65 (0.28--1.54)0.33 Rural areas^c^  Control233/45551.211  Intervention42/40310.40.20 (0.14--0.30)\< 0.0010.20 (0.14--0.29)\< 0.001Per protocol analysis All ages  Control241/54644.111  Intervention20/4384.60.10 (0.06--0.17)\< 0.0010.11 (0.07--0.17)\< 0.001 5--10 years^b^  Control122/27644.211  Intervention9/2373.80.09 (0.04--0.17)\< 0.0010.09 (0.05--0.19)\< 0.001 11--18 years^b^  Control119/27044.111  Intervention11/2015.50.12 (0.07--0.24)\< 0.0010.12 (0.06--0.23)\< 0.001 Urban area^c^  Control8/918.811  Intervention5/1064.70.54 (0.19--1.53)0.240.49 (0.18--1.38)0.18 Rural areas^c^  Control233/45551.211  Intervention15/3324.50.09 (0.05--0.16)\< 0.0010.09 (0.05--0.15)\< 0.001^a^n = 1091, excluded one child with missing bednet information. Adjusted for age group (5--10, 11--18 years); baseline community parasite prevalence (quartiles: 0--13%, 13.01--25%, 25.01--33%, \> 33%); sex; bednet use (slept under a bednet the previous night); and region (urban area vs rural areas)^b^p-value for interaction between trial arm and age group: Intention-to-treat analysis p = 0.18 for the unadjusted model and p = 0.36 for the adjusted model; per-protocol analysis p = 0.41 for the unadjusted model and p = 0.53 for the adjusted model^c^p-value for interaction between trial arm and region: Intention-to-treat analysis p = 0.02 for unadjusted model and p = 0.09 for adjusted model; per-protocol analysis p = 0.003 for the unadjusted model and p = 0.016 for the adjusted model Fig. 3Parasite prevalence by region. For each region, the shaded bars represent the control arm and the open bars represent the intervention arm, both with 95% confidence intervals

To further explore the association between the timing of DP treatment and parasite prevalence, the children in the intervention arm were stratified according to time since the last dose of DP and comparisons were made with the control arm (Table [3](#Tab3){ref-type="table"}). As expected, parasite prevalence was lowest in children who had been treated with DP within the last 28 days, but parasitaemia in children treated more remotely was also reduced. Indeed, even those children from intervention schools who had never received DP had lower parasite prevalence than control children (26.2% vs 44.1%, prevalence ratio 0.57, \[95% CI 0.40‒0.81\], p = 0.001).Table 3Association between time since last dose of DP and parasite prevalenceTreatment armDays since last dose of DPParasite prevalencePR (95% CI)^a^p-valueControlNo prior DP241/546 (44.1%)Reference groupInterventionNo prior DP44/168 (26.2%)0.57 (0.40--0.81)0.00129--113 days3/33 (9.1%)0.20 (0.06--0.64)0.0061--28 days3/345 (0.9%)0.02 (0.01--0.10)\< 0.001^a^Prevalence ratio adjusted for repeated measures within the same cluster

Impact on secondary outcomes {#Sec17}
----------------------------

The prevalence of gametocytaemia was lower in the intervention than the control arm (Table [4](#Tab4){ref-type="table"}). Moreover, children in the intervention arm were less likely to be febrile (elevated temperature or history of fever in the past 48 h) and to have symptomatic malaria (febrile with a positive rapid diagnostic test) than those in the control arm (5.1% vs 35.7%; aRR 0.14 \[95% CI 0.08‒0.26\], p \< 0.001). No differences in prevalence of anaemia or haemoglobin levels were observed between the two groups. School attendance during the study period was similar in both study arms; the total number of days students were absent from intervention schools was 141,383 out of 2,557,776 days vs 116,456 out of 2,106,774 follow-up days in control schools, a rate of 5.5 per 100 days in both groups (rate ratio: 1.02 \[95% CI 0.72‒1.43\], comparing children in the intervention vs control arm).Table 4Effect of the IPT intervention on secondary outcomes in the final school surveyn/NPrevalence (%)Crude risk ratio (95% CI)pAdjusted risk ratio (95% CI)pPrevalence of gametocytaemia Control52/5469.511 Intervention17/5463.10.33 (0.19--0.56)\< 0.0010.34 (0.20--0.56)\< 0.001Prevalence of fever Control307/54656.211 Intervention110/54620.20.36 (0.25--0.51)\< 0.0010.35 (0.25--0.50)\< 0.001Symptomatic malaria Control195/54635.711 Intervention28/5465.10.14 (0.08--0.26)\< 0.0010.14 (0.08--0.26)\< 0.001Prevalence of anaemia Control26/12620.111 Intervention24/12918.60.90 (0.54--1.51)0.690.82 (0.49--1.38)0.46Mean haemoglobin^a^ Control12612.7 (SE 0.14)00 Intervention12912.9 (SE 0.13)0.15 (− 0.22, 0.52)0.420.19 (− 0.16, 0.54)0.29^a^Measured in every 5th participant, results presented as the relative difference in mean values

Discussion {#Sec18}
==========

Intermittent preventive treatment (IPT) is a well-established malaria control intervention that is recommended for certain high-risk populations, but is not current policy for schoolchildren. In this cluster-randomized trial, IPT with DP delivered monthly to primary schoolchildren was associated with a substantial reduction in parasitaemia in all ages, particularly in rural areas. Children in the intervention arm were significantly less likely to have fever and symptomatic malaria, and also less likely to have gametocytaemia. These results contribute to the growing body of evidence that targeting chemoprevention to school-aged children provides important health benefits to individual children. Moreover, by reducing parasitaemia and particularly gametocytaemia, which might otherwise go untreated, IPT of schoolchildren stands to reduce the infectious reservoir of parasites available for onward transmission of malaria. IPT could be integrated into existing school infrastructure and programmes thus expanding the tools available to control malaria in school-aged children and the community as a whole.

In this study, a substantial number of children in the control arm were febrile and were subsequently diagnosed with symptomatic malaria by a positive RDT on the day of the survey; IPT markedly reduced the risk of fever and symptomatic malaria. There is growing awareness of the burden of malaria in school-aged children \[[@CR10]\], and the benefits of providing preventive treatment for malaria to children through school-based programmes have been examined in multiple studies \[[@CR20], [@CR28], [@CR29]\]. A recent systematic review evaluated the efficacy and safety of IPT of schoolchildren \[[@CR20]\]. Five studies, including four individually-randomized trials and one cluster-randomized trial, conducted in 2002--2012 in Kenya, Mali, and Uganda were included, which assessed a variety of anti-malarial regimens. This review suggested that the protective efficacy of IPT against parasitaemia ranged from 49% to 94% depending on the regimen; monthly IPT with DP was most effective (94% protective efficacy \[95% CI 93--96%\]). Four additional studies of school-based malaria interventions have been published since that review, including one individually-randomized trial of IPT for helminths and malaria with artemether--lumefantrine conducted in Ghana \[[@CR21]\], one individually-randomized trial of IPT for malaria with sulfadoxine--pyrimethamine (SP) and SP + piperaquine conducted in the Democratic Republic of Congo \[[@CR23]\], one cluster-randomized trial of IPT for malaria with artesunate + SP conducted in Mali \[[@CR22]\], and one individually randomized trial of SMC of schoolchildren with artesunate + amodiaquine conducted in Mali \[[@CR19]\]. Synthesis of the findings is challenged by heterogeneity of the trial designs, regimens assessed, frequency of treatment, and outcome measures. But, overall, these studies demonstrate that delivering preventive treatment to schoolchildren with combination anti-malarial regimens reduces the risk of parasitaemia, clinical malaria, and anaemia and may improve cognitive indicators.

School-aged children are important contributors to the human infectious reservoir of malaria \[[@CR13]\]. In malaria endemic areas, older children, who have acquired some anti-malarial immunity through repeated parasite exposure, may harbour asymptomatic infections which often go untreated \[[@CR11], [@CR30]\]. School-aged children often have the highest parasite prevalence within populations \[[@CR13]\], and may be more likely to carry gametocytes, the sexual stage of the parasite required for transmission \[[@CR31], [@CR32]\]. As a result, older children are a major source of malaria parasites for mosquitoes, perpetuating the transmission cycle \[[@CR12], [@CR14], [@CR33]\]. A recent study, which examined the human infectious reservoir for *Plasmodium falciparum* in Burkina Faso and Kenya, found that gametocyte carriage was common in asymptomatic individuals and that children were more likely to infect mosquitoes than adults \[[@CR14]\]. After adjusting for mosquito exposure, the proportion of mosquitoes that had been infected by children aged 5--15 years ranged from 41 to 74% in high and moderate transmission areas. In Ethiopia, a study of schoolchildren highlighted the importance of sub-microscopic parasitaemia in this age group, and the positive association between parasite density and gametocyte density for both *P. falciparum* and *Plasmodium vivax* \[[@CR34]\]. These findings are supported by another study from Burkina Faso that suggested children are an important component of the infectious reservoir and that sub-microscopic infections contribute to onward transmission \[[@CR33]\]. In the main START-IPT trial, a 15% reduction in all-age community-level malaria parasite prevalence was found, despite lower than expected intervention coverage, with the results suggesting reductions as large as 27% or as small as 0% were plausible (19.0% vs 23.1%, adjusted RR 0.85 \[95% CI 0.73‒1.00\], p = 0.05) \[[@CR24]\]. The results of this survey showing that children from the intervention schools had lower parasite prevalence than control children, even if they did not receive DP provide further evidence that IPT with DP may have some community-level effect. Taken together, these findings highlight the important role of school-aged children in malaria transmission and the need to target this age group to control and ultimately eliminate malaria in higher transmission settings.

In this study, IPT with DP was associated with a substantial reduction in parasitaemia in rural areas, but these differences were more modest in the urban area of Jinja town. Parasite prevalence in the control arm varied widely between the rural (51.2%) and urban (8.8%) areas. Reduced transmission and burden of malaria in urban settings is well-described \[[@CR35]\], likely due to a reduction in breeding sites, and improved housing construction \[[@CR36]\]. Evidence that house design can provide protection from malaria is growing \[[@CR37], [@CR38]\]. Several studies have compared houses constructed with modern materials (typically made of brick, concrete, or metal walls, tiled or metal roof, closed eaves) to those constructed with traditional materials (typically made of mud walls, thatched roof, open eaves) \[[@CR36], [@CR39], [@CR40]\]. A systematic review of studies from Africa, Asia, and Latin America suggested that residents of 'modern' homes are at lower risk of malaria infection and clinical malaria, than residents of 'traditional' houses \[[@CR36]\]. Given that children residing in urban areas may already be at lower risk of malaria than their rural counterparts, the added benefit of IPT in such settings may be lower. The potential role of IPT of schoolchildren in urban settings may need to be explored further.

Schools provide a potential platform for delivery of health programmes to older children. Schools are already targeted for malaria control interventions in Uganda, acting as sites for targeted delivery of LLINs to schoolchildren. Selected schools located in hard-to-reach areas host facility outreach distribution programmes aiming to maintain universal coverage of LLINs achieved through mass LLIN distribution campaigns led by the Ministry of Health. Schools also serve as a focal point for societal and behaviour change communication. Ugandan schoolchildren have been engaged to deliver malaria intervention messages to their families and friends, thus acting as 'change agents' within their communities \[[@CR41]\]. Although adding IPT to other school-based programmes would leverage resources and potentially save costs, low uptake of interventions may remain a challenge \[[@CR42]\], mass drug administration can feed into existing concerns and mistrust in biomedical interventions \[[@CR43], [@CR44]\], and the frequent administration of IPT will need to be taken into consideration \[[@CR45]\]. Schools provide an attractive platform for delivery of health programmes, including malaria control interventions, but potential challenges and strategies to address them should be explored and developed through operational research.

In this study, IPT with DP did not have an impact on haemoglobin levels or prevalence of anaemia. The aetiology of childhood anaemia in low- and -middle income countries is multifactorial and complex \[[@CR46]\]. However, *P. falciparum* malaria is a well-recognized risk factor for anaemia in malaria-endemic settings \[[@CR47], [@CR48]\], along with iron and nutritional deficiencies, parasitic and other chronic infections, and genetic haemoglobin disorders \[[@CR46]\]. The reason for the lack of association between IPT with DP and prevalence of anaemia in this study is unclear, however, the limited sampling of only 20% of the study population and the timing of the evaluation (at endline rather than several months after the intervention) may have contributed. Moreover, anaemia predominantly affects children under-five in Uganda and the prevalence of anaemia in this age group, as measured in the Malaria Indicator and Demographic Health Surveys, appears to be declining \[[@CR3], [@CR49]\].

This study had several limitations. First, intervention coverage in the study population was suboptimal. Only 65.2% of children enrolled in the survey from the intervention arm received at least one full dose of DP, and only 2.8% received the full 3-day course of DP in all 6 rounds of treatment. However, despite this low coverage, a marked reduction in parasitaemia was achieved in the intervention arm, even in those children who did not receive DP. Of note, IPT coverage in the school surveys, although low, was still higher than in the main trial, which does not rule out potential selection bias. Secondly, in this single cross-sectional survey of schoolchildren, outcomes were only measured at a single timepoint. Prospective evaluation of children in a longitudinally followed cohort might have been preferable, as would longer term follow-up of children to assess sustainability of impact, but resources precluded this type of evaluation. Finally, parasitaemia and gametocytaemia were only measured using microscopy, which may have underestimated prevalence measures. Indeed, there is an increasing appreciation of sub-microscopic infection and more sensitive molecular tests could have been applied, including loop mediated isothermal amplification (LAMP) or polymerase chain reaction (PCR) for asexual parasites \[[@CR50], [@CR51]\], and quantitative nucleic acid-based amplification (QT-NASBA) for gametocytes \[[@CR52]\].

Conclusions {#Sec19}
===========

In this cluster-randomized trial, IPT with DP delivered to primary schoolchildren reduced parasitaemia, gametocytaemia, fever, and symptomatic malaria. These results contribute to the growing body of evidence that targeting chemoprevention to school-aged children would benefit individual children. Moreover, IPT of schoolchildren stands to reduce malaria transmission by reducing the infectious reservoir of malaria, which could be an important new tool for countries seeking to intensify malaria control on the pathway to elimination. School-based IPT could be integrated with school infrastructure and interventions, thus leveraging existing resources while expanding the toolbox for malaria control. Future research on IPT of schoolchildren should explore strategies to achieve high coverage, approaches to integrate IPT with other school-based interventions, and cost-effectiveness, particularly in urban settings. The potential impact of IPT of schoolchildren on community-level malaria transmission should also be investigated further, ideally at higher coverage levels and in different epidemiological settings.
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:   long-lasting insecticide treated bed net

LSHTM

:   London School of Hygiene and Tropical Medicine

PCR

:   polymerase chain reaction

PR

:   prevalence ratio

QT-NASBA

:   quantitative nucleic acid-based amplification

RDT

:   rapid diagnostic test

SMC

:   seasonal malaria chemoprophylaxis

START

:   School-based Treatment with ACT to Reduce Transmission

SP

:   sulfadoxine--pyrimethamine

UCSF

:   University of California, San Francisco

UNCST

:   Uganda National Council of Science and Technology

WHO

:   World Health Organization
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